Eli Lilly and Company (NYSE:LLY) is one of the top S&P 500 stocks by index weight. On April 15, BMO Capital reiterated an ...

Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron ...

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

The U.S. Food and Drug Administration approved the pill for weight loss earlier this month, intensifying Lilly's competition ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

The FDA has approved the second GLP-1 pill for overweight and obesity. How does it compare to the Wegovy oral pill?

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

By Sriparna Roy and Sahil Pandey April 16 (Reuters) - Eli Lilly said on Thursday its newly approved obesity pill was not ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

Eli Lilly just released results of a clinical trial that may ease concerns about the safety of its new weight-loss pill ...

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital ...